Invivyd reported topline results on September 29 from LIBERTY, a Phase 3 study that put its investigational COVID antibody, VYD2311, up against an mRNA vaccine rather than a placebo. The antibody won the comparison the study was built to make. Among 210 healthy adults, 56.5 percent of those who received VYD2311 had a treatment-emergent adverse event, injection site reaction, or hypersensitivity reaction in the six days after dosing, against 91.4 percent of those who received Pfizer and BioNTech's Comirnaty. The numbers held over 56 days. No reaction attributed to the antibody rose above Grade 2, and no participant in any arm had anaphylaxis.
That is the entire result set, and the company is treating it as the foundation of a regulatory filing. The important detail is what LIBERTY did not measure. Across its three arms, no one was followed to see whether they caught COVID-19. The study compared how the two prevention strategies feel, not whether either one works, and Invivyd plans to ask the FDA to approve the antibody next year with the efficacy question still formally open.
The company disclosed its regulatory strategy in the same release, and it is the most consequential part of the announcement. Invivyd intends to submit a Biologics License Application under the FDA's Accelerated Approval Program, using safety and antibody levels from the ongoing DECLARATION trial, and to unblind the study's clinical events only after approval, if one comes. In effect, the company is proposing to win marketing approval for a COVID prevention drug on the strength of a surrogate marker, and to prove it prevents COVID later.
A study designed to measure tolerability, not protection
The LIBERTY design is straightforward once the endpoints are read carefully. Investigators randomized 210 healthy adults aged 18 to 49 into three equal groups: a single 250 milligram intramuscular dose of VYD2311, the mRNA vaccine alone, or both together. Every participant received two injections so the arms would look identical, with volume-matched placebo filling the second syringe where needed.
The co-primary endpoints were the share of participants with any treatment-emergent adverse event, injection site reaction, or hypersensitivity reaction over six days, and the share with solicited systemic side effects over the same window. The key secondary endpoint extended the first measure to 56 days. Antibody titers were measured as immunogenicity data, not as an efficacy claim.
On the systemic side effects, 44.1 percent of the VYD2311 group reported them, against 68.1 percent on the vaccine alone, a difference the company reported with a p value of 0.008. The 56-day safety comparison was 60.9 percent against 91.4 percent, with a p value below 0.0001. The combination arm reduced reactogenicity relative to the vaccine alone on the six-day measures, but those comparisons did not all reach statistical significance: the overall six-day rate was 78.9 percent with a p value of 0.057, and the 56-day rate was 83.1 percent with a p value of 0.21.
The immunology produced a finding that may outlast the safety numbers. Adding VYD2311 to the vaccine raised neutralizing titers roughly 2.5-fold over the vaccine alone across 56 days, and when the company stripped the antibody back out of the combination samples, the vaccine-induced titers were essentially identical to the vaccine-only arm. That rules out the concern that an antibody infusion could blunt a vaccine's effect, and it suggests the two approaches add to each other rather than compete. Michael Mina, the company's chief medical officer, called the combination signal a possible area of future study in COVID and other diseases.
What the FDA needs in order to approve a prevention drug
Accelerated approval exists for exactly this situation: a serious condition, a product that fills an unmet need, and an endpoint that is reasonably likely to predict clinical benefit even though it is not itself the benefit. The trade is explicit. The FDA grants approval on the surrogate, and the sponsor commits to a confirmatory study that verifies the real-world result. If the confirmatory work fails, the agency can withdraw the approval.
For COVID antibodies, the surrogate has a track record. Pemivibart, VYD2311's predecessor from the same company, was authorized in March 2024 for immunocompromised patients on the basis of an immunobridging analysis that compared its calculated antibody titers with those of adintrevimab, an earlier antibody with demonstrated clinical efficacy in the EVADE trial. That approach was later validated when pemivibart's own placebo-controlled cohort showed an 84 percent relative risk reduction in symptomatic COVID-19 through six months. Bridging from antibody levels to protection was not a shortcut that failed. It was a bet that paid off once.
Invivyd's argument, laid out in the release, is that the standards applied to its antibodies are stricter than the ones applied to the vaccines they compete with. Updated COVID vaccines are approved each season on immunogenicity data, without a fresh efficacy trial. Marc Elia, the company's chief executive, said the LIBERTY data provide more contemporary human clinical information than the data behind recently approved vaccine updates. That comparison has an obvious limit: the FDA is amending the strain composition of vaccines it has already approved, not clearing a new product with a new mechanism. Whether titers can carry a first approval for an antibody is the question the BLA will test.
The plan keeps the efficacy data sealed
The DECLARATION trial is the piece that would normally answer whether VYD2311 prevents disease. It randomized roughly 2,400 adults and adolescents, with and without risk factors for severe COVID-19, to single or monthly intramuscular doses of the antibody or placebo, and it is designed to measure prevention of symptomatic COVID-19 at three months. Enrollment completed in June. The trial is triple-blind, so neither participants, investigators, nor the company's own monitors know who received what.
The company's plan for that data is unusual. In October, it will unblind and report safety and antiviral activity. The clinical events that would show whether the antibody works will stay blinded and continue to accumulate. If the safety and titer data are supportive, Invivyd will pursue accelerated approval and then run a post-approval cohort that pools PCR-positive symptomatic cases to target a 70 to 90 percent relative risk reduction against placebo. Only then would the efficacy question be answered.
There is a statistical logic to this. Unblinding the events now, before enough cases have accumulated, would spend the study's power on an underpowered answer and leave nothing for the confirmatory analysis. But the arrangement means that for the first years of any approval, patients and doctors would be using a prevention drug whose prevention claim rests on the same bridging logic that supported pemivibart's emergency authorization, extended by a companion study that measured tolerability.
The clock runs out on the current product in June 2027
The urgency comes from an expiring authorization. HHS moved to end the COVID-19 emergency declaration, and the FDA sent Invivyd a notice giving twelve months of advance warning that the PEMGARDA authorization will terminate effective June 29, 2027. The company called the step routine, and it has a point: an emergency authorization is not an approval, and the COVID emergency is over by any reasonable definition. The practical effect is that Invivyd's only marketed product has a dated shelf life unless the company converts its antibody franchise into approved products.
The balance sheet sharpens the timeline. PEMGARDA brought in $14.3 million in net product revenue in the second quarter, while research spending on the two VYD2311 trials helped push the quarter's net loss to $44.4 million. The company ended June with $160.1 million in cash and disclosed in its quarterly filing that the money is enough to reach the DECLARATION readout but not, without new financing, to fund operations beyond a year. Invivyd also received a Nasdaq minimum bid price notice in July. A company in that position needs the accelerated approval to work, because the alternative is a terminated authorization, no approved product, and a pivotal trial that has already spent its enrollment.
The population that needs this drug is not deciding on side effects
The case for a better-tolerated option depends on who is choosing. For healthy adults, the 2025-2026 vaccine season moved to shared clinical decision-making, with the FDA limiting the updated shots to people 65 and older or those under 65 with a high-risk condition. Reactogenicity is part of why that conversation exists, and a prevention option that produces far fewer sore arms and flu-like days could, in principle, reach people who skip vaccination.
But the population where antibodies have their clearest role is immunocompromised patients, the group for which pemivibart held its authorization: people whose immune systems do not mount a useful response to vaccination at all. For them, the choice was never between an antibody and a vaccine based on side effects. It was between an antibody and nothing. LIBERTY did not enroll that population, and its tolerability advantage is an argument to regulators about risk, not to patients about preference.
The combination data are the part of the package aimed at the broader market, and they are also the least mature. If adding an antibody to a vaccine reliably cuts vaccine side effects while adding to titers, that finding would matter for vaccination itself, which reaches far more people than any antibody program. The company is presenting that possibility as a direction for future study, not a result in hand.
What October will show
DECLARATION's safety and immunogenicity data arrive next month, and they will carry more weight than LIBERTY for the approval question, because they come from the population and the design the FDA will scrutinize. Then the agency decides whether to accept an application built on antibody levels, a decision that will say as much about how far immunobridging can stretch after the emergency era as it does about Invivyd.
The company's own framing makes the wager plain: it is asking to be judged by the standard used for updated vaccines rather than the standard used for new drugs. LIBERTY answered the question Invivyd chose to ask, and answered it well. The FDA's question is narrower: whether a drug that has not been shown to prevent COVID should be approved to prevent COVID, with the proof to follow. The answer will determine whether better tolerability is enough to sell protection, and whether protection without proof still counts.
Primary sources
- Invivyd, Exhibit 99.1 to the September 29, 2026 Form 8-K, for the LIBERTY design, the endpoint results and p values, the immunologic interference analysis, the DECLARATION plan, and the accelerated approval strategy.
- Invivyd, notice of PEMGARDA emergency use authorization termination (via Wedbush/GlobeNewswire), July 6, 2026, for the June 29, 2027 termination date.
- Invivyd, second quarter 2026 financial results (via Business Insider/GlobeNewswire), August 13, 2026, for PEMGARDA revenue, the cash position, and the runway statement.
- ClinicalTrials.gov, DECLARATION trial record, for the trial design, population, and primary endpoint.
- FDA, EUA summary review for pemivibart (EUA 122), March 22, 2024, for the antibody titer comparison that supported the 2024 emergency use authorization.